WATERTOWN, Mass, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ...

Williams is rolling in defensive accolades as the 2024 Minor League Defensive Player of the Year and a 2022 Minor League Gold ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

“As we look to the primary endpoint data readout from our Phase 3 pivotal trial in the first half of next year ... $24.0 million, compared to $21.7 million for the three months ended September 30, ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline ...

Descriptive epidemiology is important for understanding causes, evaluating potential effects of policies and environmental ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33.

Jazz Pharmaceuticals plc today announced financial results for the third quarter of 2024 and updated guidance for 2024. "Jazz once again delivered record revenues ...

During the quarter ended September 30, 2024, MacroGenics announced the achievement of $100.0 million in milestones from Incyte related to development progress of retifanlimab, following an agreement ...

Financial Review for Third Quarter and Nine Months of 2024 Revenues reported were €1,244.8 million for the three months ended September 30, 2024, compared to €895.3 million for the comparative prior ...

First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...